BY MIRABEL ODETA
U.S. President Donald Trump has signed a new executive order aimed at speeding up access to medical research and treatments involving psychedelic drugs. The move signals a significant shift in how the federal government approaches substances that have long been restricted due to their hallucinogenic effects.
The order directs the U.S. Food and Drug Administration to fast-track the review process for certain experimental drugs, including ibogaine. This substance has drawn attention from U.S. military veteran groups, who argue that it shows promise in treating post-traumatic stress disorder, a condition that affects many former service members.
Speaking at an event in the Oval Office, federal officials explained that the initiative could ultimately lead to the reclassification of these drugs if ongoing and future clinical trials demonstrate their safety and effectiveness. Currently, many psychedelic substances remain illegal under federal law due to concerns about misuse and psychological risks.
Trump also announced that the federal government would commit $50 million toward research focused specifically on ibogaine. The funding is expected to support scientific studies exploring its potential therapeutic benefits, particularly in mental health treatment.
The push for alternative therapies has been strongly supported by Health Secretary Robert F. Kennedy Jr., who has advocated for the controlled medical use of psychedelic substances. He has highlighted their possible role in addressing conditions such as depression, especially in cases where traditional treatments have proven ineffective.
Meanwhile, Marty Makary, commissioner of the FDA, indicated that decisions regarding the approval or reclassification of these drugs could come as early as this summer. This timeline suggests that regulatory changes may happen sooner than expected if the evidence supports their medical use.
The executive order represents a notable development in U.S. health policy, reflecting growing interest in innovative approaches to mental health care. If successful, it could open the door to new treatment options for patients while reshaping long-standing regulations around psychedelic substances.
Original article
Comments